- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
B-YOND study results reinforce long-term clinical profile of Alprolix
18 August 2015 • Author: Victoria White
Swedish Orphan Biovitrum (Sobi) and its partner Biogen have released interim results from the B-YOND study, supporting the long-term safety and efficacy of Alprolix (rFIXFc) in people with severe haemophilia B treated for up to two years.
Participants in this Phase 3, open-label long-term study maintained low bleeding rates with one to two week prophylaxis regimens. No inhibitors have been reported to-date.
“B-YOND represents the most extensive long-term clinical data set for a long-acting replacement FIX product. These interim results support the efficacy and safety profile of Alprolix in paediatric patients as well as in adults and adolescents,” says Birgitte Volck, Chief Medical Officer at Sobi.
B-YOND is an ongoing extension study for people with severe haemophilia B who completed the Phase 3 pivotal B-LONG or Kids B-LONG study. The study’s primary endpoint is inhibitor development. From the beginning of B-LONG or Kids-B-LONG until the B-YOND interim data analysis, the cumulative median time on Alprolix was 171.6 weeks for adults and adolescents, and 95.3 weeks for children under age 12.
Study participants receiving Alprolix continue to experience low bleeding rates
Alprolix is the first recombinant, clotting factor therapy with prolonged circulation in the body for adults and children with haemophilia B, approved in the United States, Canada, Australia and Japan. Alprolix was submitted to the European Medicines Agency (EMA) for regulatory approval in Europe in June 2015.
According to the interim analysis from the B-YOND study, adults and adolescents treated prophylactically maintained protection against bleeding episodes with injections every one to two weeks. These participants had overall median annualised bleeding rates (ABR) of 2.28 for weekly prophylaxis, 2.25 for individualised prophylaxis and 2.42 for modified prophylaxis (personalised dosing if optimal prophylaxis could not otherwise be achieved). In contrast, people receiving on-demand therapy, or treatment when a bleeding episode occurred, had a median ABR of 11.27.
The median overall ABR was zero for children under age six who received weekly prophylaxis. For children six to 12 years old, median overall ABRs were 2.65, 2.37 and 3.13 in weekly, individualised and modified prophylaxis regimens, respectively. In each age group, the median average weekly dose for participants previously on prophylaxis was similar for individuals in the weekly and individualised treatment arms.
“Study participants receiving prophylactic treatment continue to experience low bleeding rates during this long-term study. The B-YOND study plays an important role in helping us understand this therapy’s long-term clinical profile and therapeutic value,” says Professor John Pasi, Professor of Haemostasis and Thrombosis at Barts and the London, United Kingdom.
Approximately 28,500 people are diagnosed with haemophilia B worldwide, according to World Hemophilia federation. Haemophilia B is caused by substantially reduced or no factor IX activity, which is needed for normal blood clotting. People with haemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life-threatening haemorrhages. Prophylactic injections of factor IX temporarily replace clotting factors necessary to control bleeding and prevent new bleeding episodes.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics